Document is current
Any future updates will be listed below
-
Authors
Gagelmann, Nico
Einsele, Hermann
Flossdorf, Sarah
Smaili, Samih
Metzeler, Klaus
Scheid, Christoph
Bullinger, Lars
Sauer, Sandra
Raab, Marc
Duyster, Justus
Reinhardt, Hans Christian
Teipel, Raphael
Alsdorf, Winfried
Lengerke, Claudia
Herr, Wolfgang
Schub, Natalie
Ayuk, Francis Ayuketang
Bassermann, Florian
Schultze-Florey, Christian
Schroers, Roland
Hänel, Mathias
Giesen, Nicola
Elmaagacli, Ahmet
Burchert, Andreas
Weber, Thomas
Mougiakakos, Dimitrios
Knop, Stefan
Müller, Fabian
Kröger, Nicolaus
Merz, Maximilian
,
-
Funding
Funding for this research was provided by:
Universität Leipzig
- License Information
-
More Information
Article History
Received: 6 April 2026
Accepted: 7 May 2026
First Online: 20 May 2026
Declarations
:
: Determined by the national registry and approval by the board. Every patient gave informed consent.
: Not applicable.
: N.G.: Adboard and Travel support: JnJ, BMS, GSK, Stemline, Pfizer, Medac, Kite/Gilead.M.M. is supported by research grants from the European Commission (CERTAINTY), Jose Carreras Leukemia Foundation, the International Myeloma Society and theHector Foundation. Honoraria: Janssen, BMS GmbH & Co KG, Amgen, Abbvie, Stemline Therapeutics, Takeda, Sanofi, Pfizer. Consulting or Advisory Role: Janssen, BMS GmbH & Co KG, Pfizer, Sanofi. Research Funding: Janssen, SpringWorks Therapeutics, Roche/Genentech. Travel, Accommodations, Expenses: Janssen, Stemline Therapeutics, Pfizer. Kite/Gilead. M.M. is supported by research grants from the European Commission (CERTAINTY), Jose Carreras Leukemia Foundation, the International Myeloma Society and the Hector Foundation. Honoraria: Janssen, BMS GmbH & Co KG, Amgen, Abbvie, Stemline Therapeutics, Takeda, Sanofi, Pfizer. Consulting or Advisory Role: Janssen, BMS GmbH & Co KG, Pfizer, Sanofi. Research Funding: Janssen, SpringWorks Therapeutics, Roche/Genentech. Travel, Accommodations, Expenses: Janssen, Stemline Therapeutics, Pfizer.
